Le Lézard
Classified in: Health, Business
Subject: OFR

First Capital REIT Announces Completion of C$300 Million Offering of Series B Senior Unsecured Debentures


/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/

TORONTO, March 1, 2024 /CNW/ - First Capital REIT ("First Capital" or the "REIT") (TSX: FCR.UN) announced today that it has closed its previously announced offering (the "Offering") of C$300 million aggregate principal amount of  Series B senior unsecured debentures (the  "Debentures") on a private placement basis in certain provinces of Canada.

The Debentures were offered on an agency basis by a syndicate of agents co?led by Desjardins Capital Markets, RBC Capital Markets and TD Securities. The Debentures were issued at par, bear interest at a rate of 5.572% per annum and will mature on March 1, 2031. Inclusive of the benefit of bond forward hedges, the REIT's all-in interest rate on the Debentures will be 5.481% per annum. 

The Debentures are rated "BBB (stable)" by DBRS.

The net proceeds of the Offering will be used to repay existing debt.

The securities offered have not been registered under the U.S.  Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About First Capital REIT (TSX: FCR.UN)

First Capital owns, operates and develops grocery-anchored, open-air centres in neighbourhoods with the strongest demographics in Canada.

www.fcr.ca 
TSX: FCR.UN

Forward?looking Statement Advisory

This press release contains forward?looking statements and information within the meaning of applicable securities laws, including statements about the use of proceeds from the Offering and the effect of bond forward hedges.  These forward?looking statements are not historical facts but, rather, reflect First Capital's current expectations and are subject to risks and uncertainties that could cause the outcome to differ materially from current expectations. Such risks and uncertainties include, among others, those discussed in First Capital's MD&A for the year ended December 31, 2023 as well as in its current Annual Information Form. Readers, therefore, should not place undue reliance on any such forward?looking statements.  First Capital undertakes no obligation to publicly update any such forward?looking statement or to reflect new information or the occurrence of future events or circumstances except as required by applicable securities laws. All forward?looking statements in this press release are made as of the date hereof and are qualified by these cautionary statements.

SOURCE First Capital REIT


These press releases may also interest you

at 07:45
Endo, Inc. announced today that its Endo Injectable Solutions business unit launched its enhanced ready-to-use product line and platform, TruDelivery®, underscoring the company's commitment to building its ready-to-administer and ready-to-use...

at 07:35
Gossamer Bio, Inc. ("Gossamer") , a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, and Chiesi Farmaceutici S.p.A ("Chiesi Group"), an...

at 07:30
Quipt Home Medical Corp. (the "Company") , a U.S. based home medical equipment provider, focused on end-to-end respiratory care, will announce its fiscal second quarter 2024 financial results on Wednesday, May 15, 2024. Gregory Crawford, Chief...

at 07:30
Spectral Medical Inc. ("Spectral" or the "Company") , a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company's Tigris trial, a Phase 3 follow-on study evaluating the use of...

at 07:30
Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a...

at 07:30
Carisma Therapeutics Inc.  ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will...



News published on and distributed by: